Merck paid $1 billion to Google Cloud for access to its agentic AI platform, and the commercial team gets there first.
The April 22 deal covers R&D, manufacturing, corporate functions, and commercial operations. Initial focus falls on how Merck creates and distributes content for healthcare providers. Agentic AI runs as autonomous systems that handle complex tasks with limited human oversight, and Merck is committing $1 billion to put that autonomy at the center of its doctor-outreach strategy.
Early deployments already include Google’s Gemini assistant for market research and building regulatory submission dossiers. Both are lower-stakes use cases, but they don’t hide where the infrastructure is heading: systematized content production at volume.
The deal lands in the middle of a specific corporate reset. Merck disclosed last year it was cutting thousands of staffers to save $3 billion annually by end of 2027. In February, it restructured around oncology, splitting other pharma offerings into a separate business unit. When asked whether AI means more cuts, the company’s spokesperson didn’t say yes: “Our competitive advantage has always been our people and our deep bench of talent.”
A $1 billion commitment to autonomous systems, layered on top of a $3 billion cost-cutting program, carries a clear arithmetic. What Merck actually buys from Google is infrastructure for scale. Whether headcount follows as that infrastructure matures is the question the spokesperson left open.
— Diana Kowalski